2022-RA-1012-ESGO The role of inflammatory markers in the preoperative diagnosis of endometrial cancer and endometrial hyperplasia

Introduction/Background

Inflammation and immunogenesis are important for cancer progression and metastasis. Blood neuthrophile lymphocyte ratio (NLR) and platelets lymphocytes ratio(PLR) are basic indicators of systemic inflamatory response, In addition high NLR is detected in patients with endometrial cancer . The aim of this study is to investigate the predictive role of NLR and PLR in cases of endometrial hyperplasia and cancer.

Methodology

This retrospective study was performed between 2015–2020 with 469 cases, 78 nonatypical endometrial hyperplasia, 28 atypical endometrial hiperplasia, 79 endometrial adenocarcinoma and 284 controls who underwent an endometrial biopsy due to abnormal uterine bleeding and had a normal histopathology in two tertiary clinics. Blood samples were drawn from all patients before endometrial biopsy . Blood cell counts, NLRs and PLRs were compared among these groups.

Results

The mean age of 469 patients was 49,01 ±49,01. The mean age was 47,49± 6,85 in group 1, 50,93 ± 10,56 in group 2, 60,95 ±8,81 in group 3 and 45,92± 6,80 in control group. The difference of age was significant between group 3 and the other groups (p<0.001). Based on lymphocyte, platelet counts and PLRs, there was no significant difference among the groups (P>0.05). The median neuthrophile counts in groups 1,2,3 and control were 3,89, 5,40, 5,30 and 3,90 respectively and there was a statistically significant difference between neuthrophile counts of the groups (p<0.001) The median NLRs in groups 1, 2, 3 and control were 1,81, 2,27, 2,60 and 1.91, respectively, There was a statistically significant difference between the NLR measurements of the cases from different groups (p<0,001⁾ .

Conclusion

As a non-specific inflammatory marker, NLR was elevated in women with endometrial cancer. Simple, cheap and easy-to-perform, the NLR can be used as a potential inflammatory marker, for endometrial malignancy.